Black Diamond Therapeutics (BDTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Black Diamond Therapeutics (BDTX) is Neutral.

The composite score behind that read is -0.13, weighing +0.06 of bullish evidence against -0.37 bearish.

Black Diamond Therapeutics last closed at $1.83, +1.10% on the session.

Against the IVW growth benchmark the position is +0.30% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for BDTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Black Diamond Therapeutics in the 21st percentile on return on equity, where 100 is best.

Black Diamond Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $103.99M.

StockMap tracks Black Diamond Therapeutics as the 281st largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Black Diamond Therapeutics ranks 245th of 381 in the group, against a group median of -0.08.